LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article: Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience.

Campogiani, Laura / Iannetta, Marco / Di Lorenzo, Andrea / Zordan, Marta / Pace, Pier Giorgio / Coppola, Luigi / Compagno, Mirko / Malagnino, Vincenzo / Teti, Elisabetta / Andreoni, Massimo / Sarmati, Loredana

Microorganisms

2023 Volume 11, Issue 2

Abstract: There are still conflicting data on the virological effects of the SARS-CoV-2 direct antivirals used in clinical practice, in spite of the documented clinical efficacy. The aim of this monocentric retrospective study was to compare virologic and ... ...

Abstract	There are still conflicting data on the virological effects of the SARS-CoV-2 direct antivirals used in clinical practice, in spite of the documented clinical efficacy. The aim of this monocentric retrospective study was to compare virologic and laboratory data of patients admitted due to SARS-CoV-2 infection from March to December 2020 treated with either remdesivir (R), a protease inhibitor (lopinavir or darunavir/ritonavir (PI)) or no direct antiviral drugs (NT). Viral load variation was indirectly assessed through PCR cycle threshold (Ct) values on the nasopharyngeal swab, analyzing the results from swabs obtained at ward admission and 7 (±2) days later. Overall, 253 patients were included: patients in the R group were significantly older, more frequently males with a significantly higher percentage of severe COVID-19, requiring more often intensive care admission, compared to the other groups. Ct variation over time did not differ amongst the three treatment groups and did not seem to be influenced by corticosteroid use, even after normalization of the treatment groups for disease severity. Non-survivors had lower Ct on admission and showed a significantly slower viral clearance compared to survivors. CD4 T-lymphocytes absolute count assessed at ward admission correlated with a reduced Ct variation over time. In conclusion, viral clearance appears to be slower in COVID-19 non-survivors, while it seems not to be influenced by the antiviral treatment received.
Language	English
Publishing date	2023-01-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720891-6
ISSN	2076-2607
ISSN	2076-2607
DOI	10.3390/microorganisms11020312
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Resistance to Ceftazidime/Avibactam in

Campogiani, Laura / Vitale, Pietro / Lodi, Alessandra / Imeneo, Alessandra / Fontana, Carla / D'Agostini, Cartesio / Compagno, Mirko / Coppola, Luigi / Spalliera, Ilaria / Malagnino, Vincenzo / Teti, Elisabetta / Iannetta, Marco / Andreoni, Massimo / Sarmati, Loredana

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 5

Abstract: Background: ...

Abstract	Background:
Language	English
Publishing date	2023-04-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12050820
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort.

Malagnino, Vincenzo / Salpini, Romina / Teti, Elisabetta / Compagno, Mirko / Ferrari, Ludovica / Mulas, Tiziana / Svicher, Valentina / Zordan, Marta / Basso, Monica / Battagin, Giuliana / Panese, Sandro / Rossi, Maria Cristina / Scaggiante, Renzo / Zago, Daniela / Iannetta, Marco / Parisi, Saverio Giuseppe / Andreoni, Massimo / Sarmati, Loredana

Viruses

2023 Volume 15, Issue 1

Abstract: The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) ... ...

Abstract	The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35−14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC.
MeSH term(s)	Humans ; Lamivudine/therapeutic use ; Hepatitis B virus/genetics ; HIV Infections/drug therapy ; Anti-Retroviral Agents/therapeutic use ; RNA ; Anti-HIV Agents/therapeutic use
Chemical Substances	Lamivudine (2T8Q726O95) ; Anti-Retroviral Agents ; RNA (63231-63-0) ; Anti-HIV Agents
Language	English
Publishing date	2023-01-10
Publishing country	Switzerland
Document type	Multicenter Study ; Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v15010193
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant

Campogiani, Laura / Crea, Angela Maria Antonia / Minardi, Maria Letizia / Ansaldo, Lorenzo / Coppola, Luigi / Compagno, Mirko / Vitale, Pietro / Spalliera, Ilaria / Malagnino, Vincenzo / Teti, Elisabetta / D'agostini, C / Pennacchiotti, Chiara / Abate, Davide Natale / Celeste, Maria Grazia / Andreoni, Massimo / Iannetta, Marco / Sarmati, Loredana

Open forum infectious diseases

2023 Volume 10, Issue 12, Page(s) ofad627

Abstract: Background: The objective of this study was to expand : Methods: This was a retrospective monocentric study including patients hospitalized (>24 hours) at Policlinico Tor Vergata, Rome, Italy, between May 1, 2021, and September 1, 2022, treated with ... ...

Abstract	Background: The objective of this study was to expand Methods: This was a retrospective monocentric study including patients hospitalized (>24 hours) at Policlinico Tor Vergata, Rome, Italy, between May 1, 2021, and September 1, 2022, treated with cefiderocol (>48 hours). The primary objective was early clinical improvement at 48-72 hours from cefiderocol start; secondary objectives were clinical success (composite outcome of infection resolution and 14-day survival), breakthrough infection, overall 30-day mortality, and cefiderocol-related adverse events. Results: Eleven patients were enrolled; 91% males (10/11), with a median age (interquartile range [IQR]) of 69 (59-71) years, 91% had ≥1 comorbidity, and 72.7% (8/11) were hospitalized in internal medicine wards. Six patients with bloodstream infection (54.5%; 4 primary, 2 central line-associated), 2 with pneumonia (18.2%), 2 with urinary tract infections (18.2%), and 1 with intra-abdominal infection (9.1%) were treated. Four patients (36.3%) presented with septic shock at cefiderocol start. Cefiderocol was used as monotherapy in 3/11 patients (27.3%), was combined with colistin in all the other 8 cases, and was used in triple combination with tigecycline in 2 patients. The median duration of treatment (IQR) was 12 (10-14) days. Early clinical improvement was documented in 8/11 patients (72.7%), clinical success in 8/11 patients (72.7%). Overall 30-day mortality was 27.3% (3/11), with death occurring a median (IQR) of 19 (17.5-20.5) days after the start of therapy. No cefiderocol-related adverse events were documented. Conclusions: Cefiderocol seems to be a safe and effective option for multidrug-resistant
Language	English
Publishing date	2023-12-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofad627
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study.

Cusato, Jessica / Borghetti, Alberto / Teti, Elisabetta / Milesi, Maurizio / Tettoni, Maria Cristina / Bonora, Stefano / Trunfio, Mattia / D'Avolio, Antonio / Compagno, Mirko / Di Giambenedetto, Simona / Di Perri, Giovanni / Calcagno, Andrea

Metabolites

2022 Volume 12, Issue 12

Abstract: Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir ...

Abstract	Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir discontinuation was assessed and analyzed by real-time PCR. We enrolled 627 participants: CA/AA carriers showed a higher prevalence of pre-existing psychiatric comorbidities and use of antidepressants. After 27.9 months, 108 participants discontinued dolutegravir, 64 for neuropsychiatric symptoms. Patients with pre-existing psychiatric comorbidities were at higher risk of dolutegravir discontinuation, while patients carrying the SLC22A2 CA/AA genotype were not. Combining the two variables, an opposite effect of SLC22A2 variants according to pre-existing psychiatric disorders was observed. Using multivariate Cox models, the combined variable pre-existing psychiatric comorbidities/SLC22A2 variants and the use of non-tenofovir alafenamide containing antiretroviral regimens were predictors of dolutegravir discontinuation for neuropsychiatric symptoms. Within 30 days, the majority of participants had a complete resolution of symptoms (61.8%), while 32.7% and 5.5% had partial or no change after dolutegravir discontinuation, respectively. Discontinuation of dolutegravir for neuropsychiatric symptoms was not uncommon and more frequent in participants with pre-existing psychiatric disorders. We described an interaction between SLC22A2 genetic variant and psychiatric comorbidities. In 38.2% of patients, a complete neuropsychiatric symptoms resolution was not observed after dolutegravir discontinuation suggesting the involvement of additional factors.
Language	English
Publishing date	2022-12-01
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662251-8
ISSN	2218-1989
ISSN	2218-1989
DOI	10.3390/metabo12121202
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production.

Alessio, Grazia / Imeneo, Alessandra / Di Lorenzo, Andrea / Rossi, Benedetta / Sorace, Chiara / Compagno, Mirko / Coppola, Luigi / Campogiani, Laura / Crea, Angela Maria Antonia / Malagnino, Vincenzo / Buccisano, Francesco / Andreoni, Massimo / Sarmati, Loredana / Iannetta, Marco

Microbiology spectrum

2022 Volume 10, Issue 5, Page(s) e0185822

MeSH term(s)	Humans ; Interferon-gamma ; COVID-19/diagnosis ; Interferon-gamma Release Tests ; Tuberculin Test ; Inflammation ; Lymphocyte Count ; Latent Tuberculosis
Chemical Substances	Interferon-gamma (82115-62-6)
Language	English
Publishing date	2022-09-13
Publishing country	United States
Document type	Letter
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.01858-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome.

Compagno, Mirko / Navarra, Assunta / Campogiani, Laura / Coppola, Luigi / Rossi, Benedetta / Iannetta, Marco / Malagnino, Vincenzo / Parisi, Saverio G / Mariotti, Benedetta / Cerretti, Raffaella / Arcese, William / Goletti, Delia / Andreoni, Massimo / Sarmati, Loredana

International journal of environmental research and public health

2022 Volume 19, Issue 17

Abstract: The results of tuberculosis (TB) screening and reactivation in a cohort of 323 adult patients undergoing haematopoietic stem cell transplantation (HSCT) from 2015 to 2019 at the University Hospital of Tor Vergata, Rome, Italy, were reported. A total of ... ...

Abstract	The results of tuberculosis (TB) screening and reactivation in a cohort of 323 adult patients undergoing haematopoietic stem cell transplantation (HSCT) from 2015 to 2019 at the University Hospital of Tor Vergata, Rome, Italy, were reported. A total of 260 patients, 59 (18.3%) autologous and 264 (81.7%) allogeneic transplants, underwent Interferon Release (IFN)-γ (IGRA) test screening: 228 (87.7%) were negative, 11 (4.2%) indeterminate and 21 (8.1%) positive. Most of the IGRA-positive patients were of Italian origin (95.2%) and significantly older than the IGRA-negative (
MeSH term(s)	Adult ; Cohort Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hospitals ; Humans ; Interferon-gamma Release Tests/methods ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/epidemiology ; Retrospective Studies ; Rome/epidemiology ; Tuberculin Test/methods ; Tuberculosis/diagnosis ; Tuberculosis/epidemiology
Language	English
Publishing date	2022-08-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2175195-X
ISSN	1660-4601 ; 1661-7827
ISSN (online)	1660-4601
ISSN	1661-7827
DOI	10.3390/ijerph191710693
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort

Malagnino, Vincenzo / Teti, Elisabetta / Compagno, Mirko / Coppola, Luigi / Salpini, Romina / Svicher, Valentina / Basso, Monica / Battagin, Giuliana / Panese, Sandro / Rossi, Maria Cristina / Scaggiante, Renzo / Zago, Daniela / Iannetta, Marco / Parisi, Saverio Giuseppe / Andreoni, Massimo / Sarmati, Loredana

Microorganisms. 2021 Feb. 15, v. 9, no. 2

2021

Abstract: The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of Human Immunodeficiency Virus (HIV) viremia in patients living with HIV (PLWH) who switch a to two-drug ... ...

Abstract	The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of Human Immunodeficiency Virus (HIV) viremia in patients living with HIV (PLWH) who switch a to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC). A retrospective observational multicenter study was conducted on 166 PLWH switching to the 2DR-3TC-based regimen: 58 HBcAb-positive and 108 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly higher percentage of subjects with very low-level viremia at all time points after switching (6th month: <31% vs. 17.6%, p = 0.047; 12th month 34% vs. 27.5%, p = 0.001; 24th month 37% vs. 34.2, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively) and a higher percentage of subjects with detectable HIV RNA greater than 20 copies/mL 12 and 24 months after switching (12 months 32% vs. 11%, p = 0.001; 24 months 37% vs. 13.9%, p = 0.003 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that an increase in age of ten years (OR 2.48 (95% CI 1.58–3.89), p < 0.0001) and the presence of HBcAb positivity (OR 2.7 (5% CI 1.05–6.9), p = 0.038) increased the risk of detectability of HIV RNA by nearly three-fold after switching to 2DR-3TC.
Keywords	Human immunodeficiency virus ; RNA ; antiretroviral agents ; lamivudine ; regression analysis ; risk factors ; therapeutics ; viremia
Language	English
Dates of publication	2021-0215
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2720891-6
ISSN	2076-2607
ISSN	2076-2607
DOI	10.3390/microorganisms9020396
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article: Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine.

Ferrari, Ludovica / Compagno, Mirko / Campogiani, Laura / Teti, Elisabetta / Mulas, Tiziana / Checchi, Davide / Alessio, Grazia / Caldara, Federica / Coppola, Luigi / De Simone, Giuseppe / Ceccarelli, Laura / Spalliera, Ilaria / Vitale, Pietro / Grelli, Sandro / Andreoni, Massimo / Sarmati, Loredana / Iannetta, Marco

Vaccines

2022 Volume 10, Issue 8

Abstract: Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 ...

Abstract	Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case−control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naïve and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naïve subjects experienced side effects more often than SARS-CoV-2 naïve subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naïve subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10−100 AU/mL) antibody titer. Among SARS-CoV-2-naïve subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naïve after the first, but not after the second dose of the BNT162b2 vaccine.
Language	English
Publishing date	2022-08-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10081238
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers.

Malagnino, Vincenzo / Cerva, Carlotta / Teti, Elisabetta / Campogiani, Laura / Compagno, Mirko / Foroghi Biland, Luca / Saderi, Laura / Armenia, Daniele / Salpini, Romina / Svicher, Valentina / Sotgiu, Giovanni / Iannetta, Marco / Andreoni, Massimo / Sarmati, Loredana

Scientific reports

2021 Volume 11, Issue 1, Page(s) 3965

Abstract: Low CD4+ cell count in patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection during combination antiretroviral therapy (cART) has been described; however, notably few studies have investigated coinfected patients ... ...

Abstract	Low CD4+ cell count in patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection during combination antiretroviral therapy (cART) has been described; however, notably few studies have investigated coinfected patients positive for antibodies to the HBV c antigen (HBcAb). An observational retrospective study enrolling 190 patients was conducted by grouping patients with respect to HBV status and recording CD4+ T cell counts and percentages (CD4%), CD8+ T cell counts and percentages (CD8%), and the CD4+ to CD8+ T cell ratio (CD4/CD8) at the time of HIV diagnosis, at the start of treatment and at months 1, 2, 3, 4, 5, 6, 12, and 24 after beginning cART. One hundred and twenty patients (63.2%) were negative for previous HBV infection, while 70 (36.8%) were HBcAb-positive. A significant increase in the CD4/CD8 ratio was recorded in HIV monoinfected subjects compared to HBV coinfected patients from months 4 to 12 from the beginning of cART (p value = 0.02 at month 4, p value = 0.005 at month 5, p value = 0.006 at month 6, and p value = 0.008 at month 12). A significant increase in the absolute count of CD8+ T lymphocytes was described from months 2 to 24 from the start of cART in the subgroup of HBV coinfected patients with an AIDS event at the onset of HIV infection. The presence of HBcAb was observed to be associated with reduced CD4/CD8 ratio growth and a significantly higher proportion of subjects with CD4/CD8 < 0.45 in the HIV/HBV coinfected group. A significant increase in the CD8 T cell count was shown up to 24 months after the initiation of effective cART in the subgroup of patients with the worst immune status.
MeSH term(s)	Adult ; CD4 Lymphocyte Count/methods ; CD4-CD8 Ratio/methods ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Coinfection/immunology ; Coinfection/virology ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; HIV-1/metabolism ; HIV-1/pathogenicity ; Hepatitis B/immunology ; Hepatitis B/virology ; Hepatitis B Antibodies/immunology ; Hepatitis B virus/metabolism ; Hepatitis B virus/pathogenicity ; Humans ; Male ; Middle Aged ; Viral Load
Chemical Substances	Hepatitis B Antibodies
Language	English
Publishing date	2021-02-17
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-021-83616-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito